Intravesical bacillus Calmette Guerin instillation in non-muscle-invasive bladder cancer: A review
|
|
- Carmel Walton
- 5 years ago
- Views:
Transcription
1 International Journal of Urology (2018) 25, doi: /iju Review Article Intravesical bacillus Calmette Guerin instillation in non-muscle-invasive bladder cancer: A review Manmeet Saluja 1 and Peter Gilling 2 1 Department of Urology, Auckland City Hospital, Auckland, and 2 Department of Urology, Tauranga Hospital, Tauranga, New Zealand Abbreviations & Acronyms BCG = bacillus Calmette Guerin CIS = carcinoma in situ EAU = European Association of Urology EORTC = European Organization for Research and Treatment of Cancer FDA = US Food and Drug Administration IL = interleukin LUTS = lower urinary tract symptoms NMIBC = non-muscleinvasive bladder cancer SWOG = Southwest Oncology Group TURBT = transurethral resection of bladder tumor UTI = urinary tract infection Correspondence: Manmeet Saluja M.B.Ch.B., Department of Urology, Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand. manmeet.saluja@gmail.com Received 14 March 2017; accepted 2 June Online publication 25 July 2017 Abstract: Intravesical bacillus Calmette Guerin has been the standard of care for highrisk non-muscle-invasive bladder cancer for 40 years. It remains one of the most successful immunotherapies ever used. Bacillus Calmette Guerin shows superior efficacy to alternative intravesical treatments, and has an established role in reducing both recurrence and progression in non-muscle-invasive bladder cancer. It remains relatively safe, and has acceptable tolerability of both local and systemic side-effects. The present review provides insights into the role of bacillus Calmette Guerin compared with alternative treatments both in primary and refractory settings. Key words: adjuvant treatment, bacillus Calmette Guerin, immunotherapy, non-muscleinvasive bladder cancer, urinary bladder neoplasms. Introduction Intravesical BCG is the gold standard treatment for intermediate- and high-risk NMIBC, and has stood the test of time for >40 years. Its role as a bladder preserving treatment is backed up with robust evidence, as it delays recurrence and progression of NMIBC. More recently, a worldwide shortage of BCG as a result of decreased supply has made us closely reflect on it use. Questions regarding appropriate patient selection, duration and dosing regimens, cost-effectiveness, and superiority over other intravesical agents have been raised. Furthermore, definitions of BCG failure and subsequent management options have been evaluated. The present review addresses and summarizes these issues, and introduces future direction and novel treatment strategies in NMIBC. History of BCG It has been nearly 100 years since the development of the BCG vaccine by Calmette and Guerin. 1 Immunotherapy was realized soon after as a cancer treatment, and BCG was investigated for many different cancer subtypes. 2 In 1976, BCG was tested as an intravesical treatment for superficial bladder cancer by Morales. 3 His initial work was promising in showing a decrease in recurrence rates. Subsequent studies confirmed the role of BCG in reducing recurrences, delaying progression and improving survival in patients with highrisk NMIBC. 4 6 After toxicity studies were carried out, it was finally approved by the FDA as an intravesical treatment in 1990 and now remains the standard of care in highrisk NMIBC. Mechanism of action Despite its clinical use for >40 years, the mechanism is not completely understood. BCG is a live attenuated form of Mycobacterium bovis, and needs an intact immune system to be effective. 7 BCG works through two mechanisms: a direct tumor response and immune response. 8 BCG attaches to urothelial cells through fibronectin, and becomes internalized by bladder cancers cell through macropinocytosis (Fig. 1). 7 BCG itself can induce cell death by apoptosis or necrosis. Bladder cancer cells activate the immune system by upregulating antigen-presenting cells (major histocompatibility complex-ii and intercellular adhesion molecule-1) and are presented to CD4 T cells. Cytokines (such as IL-1, IL-2, IL-6, IL-8, IL-10, 1L-12, tumor necrosis The Japanese Urological Association
2 Intravesical BCG in superficial bladder cancer BCG Attachment to urothelial cells Fibronectin Integrin α5β1 Processing by dendritic cells Direct cytotoxicity Internalization by bladder cancer cells Constitutive activation of macropinocytosis (PTEN, RAS, other oncogenes) Antigen presentation and cytokine release by bladder cancer cells MHC II upregulation ICAM-1 Secretion of IL-6, IL-8, GM-CSF, TNF-α Immune cell recruitment Granulocytes CD4 + Iymphocytes CD8 + Iymphocytes NK cells Macrophages Cytokine production IL-1, IL-2, IL-5, IL-6, IL-8, IL-12, IL-18, TNF-α, IFN-γ, GM-CSF Killing of cancer cells Immune-mediated cytotoxicity NK cells CD8 + Iymphocytes Macrophages TRAIL (granulocytes) Fig. 1 Mechanism of BCG. Reprinted with permission from Macmillan Publishers Ltd, Redelman-Sidi et al. 7 factor-alpha, interferon) are secreted, which recruit cytotoxic cells natural killer cells, cytotoxic T cells, neutrophils and macrophages that specifically target the tumor cells. 9 Recommended administration BCG is indicated for high-risk and intermediate non-muscleinvasive transitional cell carcinoma of the bladder (Table 1). Contraindications must be avoided to prevent local and systemic toxicity. Induction course Patients who are scheduled for BCG need to have a complete transurethral resection of tumor. Morales originally described intravesical treatment with once-weekly BCG for 6 weeks. BCG was instilled for a maximum of 2 h due to the dilution effect of urine. Once-weekly intervals were chosen, as the local side-effects last for less than a week. 3 A total of 6 weeks was chosen, as it was estimated to take that length Table 1 Indications and contraindications for BCG for NMIBC Indications High-risk NMIBC: CIS T1 High grade Multiple and recurrent and large (>3 cm) Ta low grade tumors Intermediate-risk NMIBC: One year of full dose BCG or intravesical chemotherapy Contraindications Absolute: <2 weeks post-turbt Macroscopic hematuria After traumatic catheterization Symptomatic UTI Pregnancy/lactation Active Tb Hypersensitivity to BCG Relative: Immunosuppression (Lamm, 1992) 36 Previous radiotherapy to bladder (EAU) 11 All factors must be present. Adapted from the EAU and American Urology Association guidelines. 11,18 of time for delayed hypersensitivity to take effect. This regime has been used in subsequent trials, and has persisted into routine clinical practice worldwide The Japanese Urological Association 19
3 M SALUJA AND P GILLING Maintenance course The SWOG trial had used an induction course for 6 weeks followed by three instillations weekly at 3 and 6 months, and every 6 months thereafter for 3 years. 10 Cystoscopy and cytology was initially carried out 3-monthly for the first 2 years followed by 6-monthly surveillance. This protocol has been adopted by the EAU guidelines. 11 Multiple other protocols have been described; however, a meta-analysis was unable to note any differences in outcome between the protocols. 12 Maintenance versus induction therapy alone Maintenance therapy is required to maximize the benefits of BCG compared with induction alone. 10,13 15 The SWOG trial concluded that 3-year maintenance therapy was better than induction alone in reducing both recurrence (from 59% to 41%) and progression (from 30% to 24%) at 5 years. At least 1 year of maintenance therapy is required to have superior efficacy over mitomycin therapy. 16 The EORTC trial showed that a 3-year maintenance course at full dose reduced the risk of recurrence from 52% to 25% compared with 1 year for the high-risk group. 15 However, no differences in progression or overall and disease-free survival were noted. For the intermediate risk group, a 1-year maintenance course was adequate. Maintenance therapy can lead to higher toxicity than induction alone, and there might be a dropout rate of up to 48% after 1 year. 10,17 There appears to be no increase in toxicity between 1 and 3 years. 10 Therefore, maintenance therapy is now the standard recommendation for the high-risk group. However, the duration of 1 year versus 3 years needs to be weighed against the cost and tolerability for the patient. 11 Method of administration Before instillation, patients have their urine analyzed and temperature measured. Contact precautions need to be maintained, and BCG is instilled through a urinary catheter and retained in the bladder for approximately 2 h. Patients are advised to bleach toilets after urinating for up to 6 h after the procedure and wear a condom during sexual intercourse during the entire treatment course. 18 Low dose versus standard dose Low-dose BCG was trialed in order to reduce toxicity. Some prospective studies and reviews 19 suggest that one-third dose has equivalent efficacy to full dose in high-risk patients with lesser toxicity. 20 Conflicting evidence from the EORTC study and a recent meta-analysis suggest that one-third dose is associated with a higher recurrence rate, but has no difference in toxicity, progression or survival. 13,15 One-sixth dose appears to be inferior, even in intermediate-risk disease, with no reduction of side-effects and therefore is not recommended. 21 Dose reduction could be considered in patients who cannot tolerate a full dose of BCG. 22 Therefore, the guidelines vary in recommending the optimal dosing, as current evidence is inconclusive. 11,18 Strain of BCG A meta-analysis could not decipher a difference between the different BCG strains. 12 A recent randomized control trial has inferred that the Connaught strain might be superior to Tice in reducing recurrences; however, further trials are necessary. 23 This is particularly relevant because of the worldwide shortage of BCG, where limited strains are available. Efficacy of BCG Risk of recurrence Adjuvant BCG reduces the risk of recurrence of high-grade NMIBC by 70% compared with transurethral resection alone. 24,25 For CIS, BCG has been shown to generate a complete response in up to 70 90% of cases. 10,14,26 However, recurrence in the long term might be as high as 50% with risk of progression. For multiple, large or recurrent Ta low-grade tumors (intermediate risk), BCG induction and maintenance can reduce recurrences by 24% and 31%, respectively. 27 Risk of progression Maintenance BCG is the only intravesical therapy that has level 1 evidence to show a reduction of tumor progression. 22 The EORTC meta-analysis showed a reduction of progression by 27% for intermediate- and high-risk groups including CIS and Ta tumors. 12 BCG versus intravesical chemotherapy For high-risk NMIBC, there is considerable evidence showing that maintenance BCG (of greater than 1 year duration) is superior to intravesical chemotherapy. 14,16,20 BCG decreases both recurrences by 32% and progression by 34% compared with chemotherapy. 16,24 For CIS alone, BCG reduces recurrence by 59% and progression by 26%. 14 The benefit is also noted in patients who have previously undergone intravesical chemotherapy. 28 Adding chemotherapy to BCG is not associated with superior outcomes and is therefore not recommended. 29 However, BCG has more toxicity compared with chemotherapy. 16 Therefore, for intermediate risk, maintenance intravesical chemotherapy might be a preferred option, especially if the patient is intolerant to BCG. 11,18 BCG versus early cystectomy in highgrade T1 No randomized trials have been carried out comparing intravesical BCG and early cystectomy. Trials that show early cystectomy is superior to late cystectomy have an inherent bias, as patients that have failed intravesical treatment are more likely to have aggressive tumors. It is known that 30% are pathologically upstaged after cystectomy. 30 Patients who are highest risk (i.e. T1G3 with CIS, multiple or large T1G3, The Japanese Urological Association
4 Intravesical BCG in superficial bladder cancer T1G3 in prostatic urethra, unusual histology or lymphovascular invasion) have a poorer prognosis. 11 Therefore, early cystectomy is likely to have a superior outcome and should be offered. Other risk factors that would support an early cystectomy include a young age (<60 years), incomplete resection and high-grade T1 in a bladder diverticulum. 31 Radical cystectomy is associated with significant treatment morbidity and potential mortality; therefore, benefits should be outweighed against the risks. Side-effects/complications Complications can either be local or systemic (Table 2). Minor local reactions are common and usually non-preventable. However, they are usually mild, transient and easily managed. 32 LUTS are the most common, occur due to the generated inflammatory response and usually respond to symptomatic management. Low-grade fever is associated with flu-like symptoms, and usually lasts for h. Urinary tract infection needs to be excluded or treated before administering subsequent doses of BCG. A single-dose quinolone 6 h after instillation might decrease side-effects and improve tolerability. 33 Severe systemic complications occur in <5% of patients, and can be potentially life threatening. These occur as a result of systemic absorption, and can be prevented by careful patient selection and safe administration practices. They require involvement of infectious disease physicians and require antituberculous medications for 3 6 months. 32,34 BCG sepsis is a rare event, but carries up to 50% mortality. 35 Patients might have a persistent high-grade fever or show signs of septic shock. Patients require urgent resuscitation, tuberculosis triple therapy, high-dose steroids and broad-spectrum antibiotics. 36 Table 2 Local and systemic complications of BCG Incidence rate (%) Management Local LUTS Rule out UTI. Treat symptoms Hematuria 1 40 Rule out UTI and recurrence UTI 5 Antibiotics Ureteric obstruction 0.3 Withhold BCG. De-obstruct ureter Contracted bladder <1 Withhold BCG. Hydrodistension Systemic Low grade fever <38.3 C High grade fever >39.4 C Granulomatous prostatitis (1%) 30 Rule out UTI. Treat symptoms 2.9 Withhold BCG. Treat symptoms 1 Antibiotics anti Tb therapy 3 6 months Epididymitis 0.2 Anti Tb therapy 3 6 months Granulomatous <1 Anti Tb therapy steroids hepatitis/ pneumonitis BCG sepsis 0.4 Antibiotics/anti Tb therapy/steroids Allergy/skin rash 0.5 Withhold BCG, antihistamines Adapted from Koya et al., 32 Lamm, 36 Rischmann et al. 34 and EAU Guidelines. 11 BCG failure Rate of BCG failure is as high as 50% in the long term. 37 BCG failure has multiple definitions described by different panels (Table 3). 11,37 Patients who have the highest risk are more likely to have BCG failure and are recommended to have early cystectomy. Women and patients aged older than 70 years also appear to be less responsive to BCG. 38,39 FISH or UroVysion assays of urine samples have been proposed to predict BCG failure, but are yet to be tested in a randomized fashion. 37 Similarly, analysis of patient s inflammatory response, immunohistochemistry or genomics might help in predicting failure. The CUETO group has formulated a predictive model for risk of recurrence and progression after BCG; however, their model has limitations that make it less applicable. 18 Management of BCG failure It has been recognized that high-grade tumor recurrence despite BCG infers a poor prognosis; and further, BCG is associated with an additional response in up to 20% of cases and an increased risk of progression. 40,41 Radical cystectomy is therefore the gold standard recommendation in patients with BCG refractory disease of patients with high-grade recurrence, with long-term survival rates exceeding >90% at 10 years. 42 In recurrent CIS, an additional BCG course can achieve a response in 30 50% of cases; however, it is rarely durable, therefore radical cystectomy remains the optimal treatment. 14 Persistent low-grade tumor recurrences are not classified as BCG failure, and can be treated by re-resection and further intravesical therapy. 11 Multiple intravesical agents have been used in a BCG refractory setting, where radical cystectomy is not an option or not preferred by the patient. These might be in the form of monotherapies with immunotherapy or chemotherapy, combination therapy or device-assisted therapies (Table 4). Valrubicin is the only FDA-approved intravesical therapy that can be used in this context. Gemcitabine has been extensively studied in the salvage setting with variable results. Addition of interferon to BCG might have a limited role, as it appears to have similar efficacy rates to BCG alone. 58 In general, chemotherapy appears to be superior to immunotherapy in a refractory setting, as they have a different mechanism of action. Combination therapies tend to be more efficacious than monotherapy. However, these studies are limited by small patient numbers and poor evidence. Even at best, these therapies yield modest responses, which are not Table 3 BCG failure: international consultation on bladder tumour definition 37 Category Intolerance Resistance Relapse Refractory Definition Intolerant of at least one induction course Recurrence or persistence of lesser stage or grade after initial course which then resolves with further BCG Recurrence after initial resolution Persistance or progression despite BCG 2017 The Japanese Urological Association 21
5 M SALUJA AND P GILLING durable and have not been shown to prevent progression or survival. 43 Future of BCG Various methods have been developed in order to improve the efficacy of BCG, through applying basic science. 61 These range from improving BCG absorption and augmenting the immune response through toll-like receptor agonists. These have had promising results in vitro, and animal studies and clinical trials are pending. Recombinant BCG strains expressing IL-2 and interferon-alpha are also currently being researched and validated. 56,57 Immune check-point inhibitors, such as actezolizumab, have proven to be effective in metastatic bladder cancer, and there is optimism on its role in the NMIBC setting. 57,58 Multiple phase I/II trials are currently underway to explore various immunotherapy agents mainly in the BCG refractory settings. This includes oncolytic viruses, such as recombinant adenovirus (CG00700), immune-modulators (ALT-801, HS- 410, ALT-803), cancer vaccines (PANVAC) and targeted kinase inhibitors (sunitinib, dovitinib, erlotinib). 18 Multiple novel strategies have been used both in primary and BCG refractory settings in order to improve outcomes (Table 4). 58 Electromotive therapy allows a chemotherapy agent to be transported across the bladder urothelium through a process called iontophoresis and aids in improved penetration. Thermochemotherapy can potentiate the effect of chemotherapeutic agents using radiofrequency hyperthermia. Photodynamic therapy uses specific wavelengths of light to activate a topical administration of a photosensitizer agent into the bladder. Device-assisted therapy allows various intravesical drug delivery devices to be implanted in the bladder. These increase the dwell time of intravesical drugs, as they are left in for an extended period of time. 60 These strategies are still in their experimental stages with limited evidence, but might become more applicable in the future. 11 Radiotherapy has historically not been shown to be effective in the management of NMIBC. However, one non-randomized trial has shown good response rates (70% progression free survival at 10 years), and chemoradiation could be a viable alternative for patients with T1 NMIBC instead of intravesical treatments. 59 Two different chemoradiotherapy regimes are currently being evaluated as part of the RTOG 0926 trial to evaluate efficacy in T1 patients who have failed BCG treatment. Additionally, compliance with BCG needs to be improved within institutions through regional audits and education. Improved tumor detection and resection strategies, and optimal surveillance regimes are currently being studied to complement BCG treatment. 18 The worldwide shortage of BCG needs to be addressed with increased production and research into new strains. Finally, the optimal dosing and duration of BCG needs to be identified in order for it to remain costeffective. Table 4 Intravesical treatment options for BCG failure Author No. patients (n) Recurrence free survival Monotherapies Gemcitabine Dalbagni et al % at 1 year Skinner et al % 1 year 21% 2 years Di Lorenzo et al % 2 years Docetaxel Barlow et al % at 1 year 25% at 3 years Valrubicin Steinberg et al % 6 months 8% 30 months Combination therapy BCG and interferon Joudi et al % 2 years Gemcitabine/ mitomycin Gemcitabine/ docetaxel Cockerill et al % at 22 months Lightfoot et al % at 1 year 38% at 2 years Steinberg et al % at 1 year 34% at 2 years Novel strategies Thermochemotherapy Nativ et al % at 2 years Photodynamic therapy Electromotive therapy Nseyo et al % at 1 year Lee et al % 1 year 64.4% 2 years Di Stasi et al % at 1 year Only FDA approved therapy for BCG refractory CIS. Conflict of interest None declared. References 1 Calmette A, Guerin C. La vaccination preventive contre la tuberculose par le BCG. Paris Masson 1927; 73: Pearl R. Cancer and tuberculosis. Am. J. Hygiene 1929; 9: Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 1976; 116: Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol. 1980; 124: Camacho FJ, Pinsky CM, Herr HW, Whitmore WF, Oettgen HF. Treatment of superficial bladder cancer with intravesical BCG. Proc. Am. Soc. Clin. Oncol. 1980; 21: Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J. Urol. 2008; 179: Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer a current perspective. Nat. Rev. Urol. 2014; 11: Jackson A, Alexandroff A, Fleming D, Prescott S, Chisholm G, James K. Bacillus-Calmette-Guerin (BCG) organisms directly alter the growth of bladder-tumor cells. Int. J. Oncol. 1994; 5: Kapoor R, Vijjan V, Singh P. Bacillus Calmette-Guerin in the management of superficial bladder cancer. Indian J. Urol. 2008; 24: Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: Babjuk M, Bohle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update Eur. Urol. 2017; 71: The Japanese Urological Association
6 Intravesical BCG in superficial bladder cancer 12 Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: Zhu S, Tang Y, Li K et al. Optimal schedule of Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer 2013; 13: Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette- Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2005; 174: Oddens J, Brausi M, Sylvester R et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 2013; 63: Bohle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169: Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R. Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol. Int. 2016; 96: Chang SS, Boorjian SA, Chou R et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol. 2016; 196: Zeng S, Yu X, Ma C et al. Low-dose versus standard dose of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine 2015; 94: e Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 2005; 174(4 Pt 1): Ojea A, Nogueira JL, Solsona E et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur. Urol. 2007; 52: Kassouf W, Traboulsi SL, Kulkarni GS et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can. Urol. Assoc. J. 2015; 9: E Rentsch CA, Birkhauser FD, Biot C et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur. Urol. 2014; 66: Malmstrom PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur. Urol. 2009; 56: Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst. Rev. 2000; CD Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. Int. J. Urol. 2008; 15: Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am. J. Clin. Oncol. 2004; 27: Houghton BB, Chalasani V, Hayne D et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int. 2013; 111: Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pt1g3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur. Urol. 2008; 53: Daneshmand S. Determining the role of cystectomy for high-grade T1 urothelial carcinoma. Urol. Clin. North Am. 2013; 40: Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J. Urol. 2006; 175: Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J. Urol. 2006; 176: Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur. Urol. 2000; 37(Suppl 1): Paterson DL, Patel A. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. Aust. N. Z. J. Surg. 1998; 68: Lamm DL. Complications of Bacillus Calmette-Guerin immunotherapy. Urol. Clin. North Am. 1992; 19: Kamat AM, Flaig TW, Grossman HB et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol. 2015; 12: Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette- Guerin: multivariate analysis of data from four randomized CUETO trials. Eur. Urol. 2008; 53: Oddens JR, Sylvester RJ, Brausi MA et al. The effect of age on the efficacy of maintenance Bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study Eur. Urol. 2014; 66: Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J. Urol. 2000; 164(3 Pt 1): Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol. 1987; 137: Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol. Oncol. 2004; 22: Steinberg RL, Thomas LJ, Nepple KG. Intravesical and alternative bladderpreservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin. Urol. Oncol. 2016; 34: Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in Bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 2006; 24: Skinner EC, Goldman B, Sakr WA et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette-Guerin. J. Urol. 2013; 190: Di Lorenzo G, Perdona S, Damiano R et al. Gemcitabine versus Bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116: Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to Bacille Calmette- Guerin therapy. BJU Int. 2009; 104: Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette- Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 2000; 163: Joudi FN, Smith BJ, O Donnell MA. National BCGIPIG. Final results from a national multicenter phase II trial of combination Bacillus Calmette-Guerin plus interferon alpha-2b for reducing recurrence of superficial bladder cancer. Urol. Oncol. 2006; 24: Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int. 2016; 117: Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O Donnell MA. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol. Oncol. 2014; 32: 35; e The Japanese Urological Association 23
7 M SALUJA AND P GILLING 52 Steinberg R, Thomas LJ, O Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non- muscle invasive bladder cancer. Bladder Cancer 2015; 1: Nativ O, Witjes JA, Hendricksen K et al. Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin. J. Urol. 2009; 182: Nseyo UO, Shumaker B, Klein EA, Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J. Urol. 1998; 160: Lee JY, Diaz RR, Cho KS et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy. J. Urol. 2013; 190: LaRue H, Ayari C, Bergeron A et al. Toll-like receptors in urothelial cells targets for cancer immunotherapy. Nat. Rev. Urol. 2013; 10: Donin NM, Lenis AT, Holden S et al. Immunotherapy for the treatment of urothelial carcinoma. J. Urol. 2017; 197: Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 2003; 170: Kamat AM, Colombel M, Sundi D et al. BCG-unresponsive non-muscleinvasive bladder cancer: recommendations from the IBCG. Nat. Rev. Urol. 2017; 14: Weiss C, Wolze C, Engehausen DG et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 2016; 24: Douglass L, Schoenberg M. The future of intravesical drug delivery for nonmuscle invasive bladder cancer. Bladder Cancer 2016; 2: The Japanese Urological Association
The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationTHE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER
THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean
More informationIntravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationKyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after
More informationSequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
Bladder Cancer 1 (2015) 65 72 DOI 10.3233/BLC-150008 IOS Press Research Report 65 Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Ryan
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationManagement of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS
Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationSymptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography
Original Article ISSN 2465-8243(Print) / ISSN: 2465-8510(Online) https://doi.org/10.14777/uti.2017.12.1.42 Urogenit Tract Infect 2017;12(1):42-48 http://crossmark.crossref.org/dialog/?doi=10.14777/uti.2017.12.1.&domain=pdf&date_stamp=2017-04-25
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationManagement options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
More informationSUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationBeware the BCG Failures: A Review of One Institution's Results
European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological
More informationImproving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer
european urology supplements 5 (2006) 654 659 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression
More informationEfficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
S86 Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer Donald L. Lamm Department of Urology, West Virginia University, Morgantown In the United States, bladder cancer
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More information/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/05/1741-0086/0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162059.64886.1c BACILLUS CALMETTE-GUERIN
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationBCG Unresponsive NMIBC: What s Available?
BCG Unresponsive NMIBC: What s Available? Michael S. Cookson, MD, MMHC, FACS Professor and Chair Department of Urology University of Oklahoma TwiLer @uromc Professional Practice Gap Gap 1: There is incomplete
More informationIntravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure
Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.
More informationBCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients
BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients Michael S. Cookson, MD, Professor and Chair Department of Urology University of Oklahoma Non-muscle Invasive Bladder Cancer Bladder
More informationThe value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice
48 Original Paper UROLOGICAL ONCOLOGY The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice Rafał Walczak, Krzysztof Bar 2, Janusz Walczak Department
More informationEUROPEAN UROLOGY 56 (2009)
EUROPEAN UROLOGY 56 (2009) 247 256 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Bladder Cancer Editorial by Guido Dalbagni on pp. 257 258 of this issue
More informationPharmacologyonline 3: (2006)
INTRAVESICAL MISTLETOE EXTRACT FOR ADJUVANT TREATMENT OF SUPERFICIAL URINARY BLADDER CANCER P. Bühler 1, C. Leiber 1, M. Lucht 2, P. Wolf 1, U. Wetterauer 1, U. Elsässer-Beile 1 1 Department of Urology,
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationNon Muscle-Invasive Bladder Cancer: Intravesical Treatments Beyond Bacille Calmette-Guerin
Non Muscle-Invasive Bladder Cancer: Intravesical Treatments Beyond Bacille Calmette-Guerin Vignesh T. Packiam, MD; Scott C. Johnson, MD; and Gary D. Steinberg, MD An unmet need exists for patients with
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationONCOLOGY LETTERS 11: , 2016
ONCOLOGY LETTERS 11: 2751-2756, 2016 Comparison of intravesical bacillus Calmette Guerin and mitomycin C administration for non muscle invasive bladder cancer: A meta analysis and systematic review SHANG
More informationRisk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD
Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer Eila C. Skinner, MD Professor, Department of Urology Stanford University SWIU Winter Meeting January, 2015 Goals Minimize treatment for patients
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationINTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 26 (3): 242-249, May - June, 2000 INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL
More informationObjectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international
More informationT1HG Bladder Cancer What is the Best Therapy?
T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction
More informationThe Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer
EUROPEAN UROLOGY 57 (2010) 410 429 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Bladder Cancer The Role of Bacillus Calmette-Guérin in the Treatment
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More informationNovel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia
Novel therapeutic strategies for NMIBC Peter Black Vancouver Prostate Centre University of British Columbia Financial and Other Disclosures I have the following financial interests or relationships to
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationRITE Thermochemotherapy in the treatment of BCG refractory NMIBC
RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationIAUN Conference Dublin, January Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist
IAUN Conference Dublin, January 2014 Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist Theoretical component Observation Supervised practice Assessment
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationSociety for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the
More informationimedpub Journals
Research Article imedpub Journals www.imedpub.com Journal of Clinical Medicine and Therapeutics Preventive Treatment with Diclofenac Suppositories May Improve BCG Induced Cystitis Symptoms without Affecting
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationCAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS
ADULT UROLOGY CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS RUI FA HAN AND JIAN GANG PAN ABSTRACT Objectives.
More informationBacille-Calmette-Guerin non-responders: how to manage
Review Article Bacille-Calmette-Guerin non-responders: how to manage Friedrich-Carl von Rundstedt 1,2, Seth P. Lerner 1 1 Scott of Department of Urology, Translational Biology and Molecular Medicine, Dan
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of electrically-stimulated intravesical chemotherapy for superficial bladder
More informationMixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
More informationResearch Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C
Bladder Cancer 1 (2015) 143 150 DOI 10.3233/BLC-150020 IOS Press Research Report 143 Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative
More informationNon-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor
Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell
More information14th Meeting of the EAU Section of Oncological Urology (ESOU)
Is Bacillus Calmette-Guerin (BCG) still the best adjuvant treatment after Trans Urethral Resection (TUR) for Ta-T1 high grade (G3) bladder cancer M. Brausi, Modena (IT) Introduction Bacillus Calmette-Guerin
More informationProtocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008
Protocol for BCG + maintenance, Donald L. Lamm, MD Last Updated Friday, 14 November 2008 {niftybox width=180px,float=right,textalign=left} update on the protocol: from Dr. Lamm's site: It is also true
More informationMANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS
MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS This symposium took place on 12 th March 2016 as part of the European Association of Urology Congress 2016 in Munich, Germany
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationOriginal Article APMC-276
Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan
More informationPhase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer
Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer K. Hendricksen,* E. B. Cornel, T. M. de Reijke, H. C. Arentsen, S. Chawla and J. A. Witjes
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationReview Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
Review Article Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer Ashish M. Kamat,*, J. Alfred Witjes, Maurizio Brausi, Mark Soloway,jj Donald Lamm, Raj Persad, Roger
More informationMICHAEL A. O DONNELL,* JANICE KROHN AND WILLIAM C. DEWOLF
0022-5347/01/1664-1300/0 THE JOURNAL OF UROLOGY Vol. 166, 1300 1305, October 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-
More informationUpdate on bladder cancer diagnosis and management
7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there
More informationContents of Online Supporting Information. etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone
Contents of Online Supporting Information etable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone etable 2. Study characteristics of head to head trials of intravesical therapy
More informationICUD-EAU International Consultation on Bladder Cancer 2012: Non Muscle-Invasive Urothelial Carcinoma of the Bladder
EUROPEN UROLOGY 63 (2013) 36 44 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer ICUD-EU International Consultation on Bladder Cancer 2012: Non Muscle-Invasive
More informationCopyright: DOI link to article: Date deposited: This work is licensed under a Creative Commons Attribution 4.0 International License
Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-Risk Non-Muscle-Invasive Bladder Cancer Therapy Options During Intravesical BCG Shortage. Current Urology Reports 2016, 17, 68. Copyright:
More informationOptimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS
Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.
More informationbetter time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed
0022-5347/00/1634-1124/0 THE JOURNAL OF UROLOGY Vol. 163, 1124 1129, April 2000 Copyright 2000 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationClinical Practice Recommendations for the Management of Non Muscle Invasive Bladder Cancer
european urology supplements 7 (2008) 651 666 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder
More informationNaim B Farah 1*, Rami Ghanem 2 and Mahmoud Amr 3
Farah et al. BMC Urology 2014, 14:11 RESEARCH ARTICLE Open Access Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial
More informationDiagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationContemporary management of high-grade T1 bladder cancer Arnulf Stenzl
Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)
More informationMark Kowalski, Jacinthe Guindon, Louise Brazas, Celine Moore, Joycelyn Entwistle, Jeannick Cizeau, Michael A. S. Jewett* and Glen C.
A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin Mark Kowalski, Jacinthe Guindon,
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationTHE SIDE EFFECTS OF THE ADJUVANT INSTILLATIONAL TREATMENT WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 1-2011 THE SIDE EFFECTS OF THE ADJUVANT INSTILLATIONAL TREATMENT WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER
More informationTheralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated
Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated First Four Patients Treated with Company s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationMaintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer
710 Maintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer How Much Is Enough? Marc Decobert, PhD Helène LaRue, PhD François Harel, MSc François Meyer, MD Yves Fradet, MD Louis
More informationA rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases
MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationComparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer
EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this
More informationBJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy
2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive
More informationREVIEW. Abstract. Pathology. Introduction. Initial resection. Repeat resection. Kenneth G. Nepple, MD; Michael A. O Donnell, MD
REVIEW The optimal management of T1 high-grade bladder cancer Kenneth G. Nepple, MD; Michael A. O Donnell, MD Abstract Stage T1Hg bladder cancer should be considered an aggressive and potentially lethal
More informationIntravesical Gemcitabine: State of the Art
european urology supplements 6 (2007) 809 815 available at www.sciencedirect.com journal homepage: www.europeanurology.com Intravesical Gemcitabine: State of the Art Paolo Gontero *, Alessandro Tizzani
More informationEffectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up
Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 121-126, 2007 in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up SAMIR EL-GHOBASHY, M.D.; TAREK R. EL-LEITHY,
More information